🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Good luck!!!

society.asco.org/about-asco/asc… Petros fans!!! Full support to his candidacy #ASCO elections. Good luck Petros Grivas

Clinically relevant anti-tumor activity of the MDM2 antagonist brigimadlin in advanced dediff. liposarcoma in first line in Phase II/III study Brightline-1: 22.3% objective responses and 86.5 % disease control rate, confirming earlier Phase 1 data. Schöffski et al., CTOS 2024

Superior activity of MDM2 antagonist brigimadlin in „locally advanced“ and „prior surgery“ subsets of patients with dedifferentiated liposarcoma in Brightline-1: a strong argument for a neoadjuvant or perioperative trial in relapsing retroperitoneal disease?

Had an email today from a pediatric oncologist from Israel asking for my advice for a 6 yo Palestinian boy with a rare sarcoma. We started chatting and she concluded: „we’ll always take care of our children regardless of everything - love will conquer hate!“ Cannot agree more!

Pre- masterclass dinner! Happy to introduce to Prime Minister GR the top of #sarcoma community all over the world! IOANNIS BOUKOVINAS Dionysios Papachristou ANASTASIOS KYRIAZOGLOU Kjetil Boye Silvia Stacchiotti @seppobauer Robin Lewis Jones Ioanna Nixon William Tap Javier Martin Broto

‼️mTOR and/or PI3K inhibitors can be an effective treatment in #GIST SDH-deficient 🧬Activating mutations in the PI3K/mTOR pathway in relapsed/mts samples 💊Sustained 55-months response with everolimus 🧐We provide other insights on tumor evolution 📰ascopubs.org/doi/10.1200/PO…

Congrats to César Serrano García and his lab for this amazing work!

Congratulations to Breelyn Wilky, MD 🎗 for this amazing work! No doubts that immunotherapy is part of our treatment armamentarium in sarcomas.

FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumor. Vimseltinib achieved a 40% ORR in #TGCT patients, significantly outperforming placebo in the MOTION trial. ⁦TGCT Support⁩ ⁦The Life Raft Group⁩ #sarcoma onclive.com/view/fda-appro…

Pan-cancer analysis of oncogenic MET fusions reveals distinct pathogenomic subsets with differential sensitivity to MET-targeted therapy | Cancer Discovery | American Association for Cancer Research aacrjournals.org/cancerdiscover…

🗓 Today is #RareDiseaseDay ✍️ Quick facts: -20-25% of all cancers -worse outcomes than common tumors -benefit from expertise and referral centers -little molecular insights -need for alternative drug development +specific education on #RareCancers ➡️ New ESMO - Eur. Oncology journal!👇🏼👇🏼

🎓 On Feb 22, the 2nd Propaedeutic Dept. of Internal Medicine University of Athens welcomed international med students from 🇺🇸🇨🇦🇬🇧🇨🇾🇫🇷 for clinical rotations! Our faculty & consultants are excited to guide them in a diverse, enriching academic environment. Welcome! 🩺✨ #NKUA

Treatment approach of #TGCT wrapped up. #esmorarecancers25 #sarcoma

Happy to share the preliminary data of our study in #osteosarcoma on the expression of Trop2 and Nectin4. In pursuit of a target. #esmorarecancers25 #sarcoma Thanks to our rising star Annita Boulouta and our professor Amanda Psyrri for the support.

Dr Toulmond discussing neoadjuvant treatment in soft tissue #sarcomas highlighting our work on pathologic complete response. Once again congrats to Annita Boulouta and thanks to Amanda Psyrri for the space and trust to run sarcoma studies. #esmorarecancers25

Η Συντονιστική Επιτροπή των ΟΝΕΟ διοργάνωσε, για 3η συνεχόμενη χρονιά, το Mentoring με μεγάλη επιτυχία! Στο πλαίσιο του 31ου ΕΣΚΟ πραγματοποιήθηκε ανοιχτή συνάντηση με τους Νέους Ογκολόγους, όπου συζητήθηκε η αξία του mentoring και ανταλλάχθηκαν εμπειρίες και πολύτιμες συμβουλές.

UEFA champions league final #ASCO25 Football meets oncology congress Best session ever!🤪

A tough trekking distance of 10 kilometres! Completed by our tough sarcoma fighters! #sarcomaawereness Thank you for the lessons you are teaching us!!

The European Medicines Agency’s Committee for Medicinal Products has recommended granting marketing authorization for nirogacestat for the treatment of adults with progressing desmoid tumors. See also c.peerview.com/live/programs/…